STAT3 and breast carcinoma: Inhibition of STAT3 activity using a pharmacological inhibitor of JAK (ruxolitinib) decreased PLOD2 expression in adipocyte cocultured MDA-MB-231 and MDA-MB-468 breast cancer cells (Fig. 6a, Additional file 5: Figure S4a).